Nomura Reiterates Bullish Stance on Celgene (CELG) Following Breast Cancer Symposium
Tweet Send to a Friend
Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating and $136 price target on Celgene (NASDAQ: CELG) after positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
